Tempus AI, Inc. (NASDAQ:TEM), a technology company advancing precision medicine through the practical application of artificial intelligence, today announced it has been named to TIME's 10 Most Influential Health and Life Science Companies of 2026. The inaugural TIME100 Companies: Industry Leaders list, an expansion of the TIME100 Most Influential Companies issue, recognizes organizations shaping the future of their sectors through extraordinary impact and innovation.

Tempus was recognized for its leadership in bridging the gap between data and technology to make genomic testing and clinical analysis more intelligent for patients. In naming Tempus to its list of the most influential companies, TIME highlighted the impact of xT CDx, Tempus' FDA-approved 648-gene tissue-based NGS test for molecular profiling of all malignant solid tumors. The recognition also noted Tempus' acquisition of Ambry Genetics, which integrated comprehensive germline and pediatric capabilities into the Tempus ecosystem. Additionally, TIME underscored Tempus' collaborations with industry leaders, including its collaboration with AstraZeneca and Pathos AI to develop the largest multimodal foundation model in oncology.

"This recognition from TIME speaks to our team's focus on building a more connected and data-driven healthcare ecosystem," said Eric Lefkofsky, Founder and CEO of Tempus AI. "We started Tempus with the belief that every patient should benefit from the data of those who came before them. Being named one of TIME's 10 Most Influential Health and Life Science Companies of 2026 reflects the meaningful strides we've made toward advancing precision medicine as the standard of care. We're thankful for the clinicians and partners who collaborate with us as we continue scaling AI-driven insights across oncology, cardiology, neuropsychiatry, and beyond."

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit www.tempus.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding expected outcomes and statements regarding Tempus' inclusion on TIME's list of the 10 most influential health and life sciences companies. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "going to," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus' products and services; Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" in Tempus' Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission ("SEC") on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260428456632/en/

Tempus

Hanah Heintzelman

hanah.heintzelman@tempus.com

Tempus Named to TIME's 10 Most Influential Health and Life Science Companies of 2026